Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, California South Korea
National Cancer Center, Goyang-si, Gyeonggi-do Chungbuk National University Hospital, Cheongju-si, North Chungcheong Seoul National University Hospital, Seoul Asan Medical Center, Seoul Samsung Medical Center, Seoul The Catholic University, St. Mary's Hospital, Seoul Yonsei University Health System, Severance Hospital, Seoul The Catholic University, St. Vincent's Hospital, Suwon Thailand
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok